Eltrombopag

證據等級: L5

預測適應症: 1 個

Eltrombopag: From Immune Thrombocytopenia to HIV Infectious Disease

One-Sentence Summary

Eltrombopag is a thrombopoietin receptor (TPO-R) agonist, historically used to treat immune thrombocytopenia (ITP) and thrombocytopenia associated with chronic liver disease and hepatitis C. The TxGNN model predicts it may be effective for HIV infectious disease, with 5 clinical trials and 9 publications currently identified — though nearly all evidence relates to managing HIV-associated thrombocytopenia rather than HIV infection itself.

Quick Overview

Item	Content
Original Indication	Immune thrombocytopenia (ITP) / thrombocytopenia in chronic liver disease — inferred from mechanism and literature context (Norway license data not available)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.26%
Evidence Level	L4 (preclinical / mechanism-level evidence)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, eltrombopag is a thrombopoietin receptor (TPO-R) agonist that stimulates megakaryocyte proliferation and platelet production. Its efficacy in ITP is well established, and it has been used off-label for thrombocytopenia secondary to chronic infections (HCV, HIV, H. pylori).

The connection to HIV, however, is largely indirect: the bulk of clinical trial and literature evidence supports using eltrombopag to manage thrombocytopenia that occurs as a complication of HIV infection (including HIV-associated ITP and immune reconstitution inflammatory syndrome-related thrombocytopenia) — this is supportive/symptomatic management of a comorbidity, not antiviral treatment of HIV itself. One in vitro screening study (PMID 32977702) suggests eltrombopag may modulate HIV-1 proviral transcription, but this finding is preliminary, derived from an FDA-approved drug library screen, and has not been validated in cell culture models beyond the initial screen, animal models, or clinical trials.

The high TxGNN score (99.26%) likely reflects a strong "drug–thrombocytopenia–HIV comorbidity" path in the knowledge graph rather than a genuine antiviral mechanism. The predicted indication label "HIV infectious disease" may therefore be imprecise — the more accurate and evidence-supported indication would be "HIV-associated thrombocytopenia."

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00678587	Phase 3	Terminated	292	Eltrombopag to reduce need for platelet transfusion in chronic liver disease patients with thrombocytopenia undergoing invasive procedures; not HIV-specific
NCT00996216	Phase 3	Completed	27	Open-label rollover study assessing safety of eltrombopag to maintain platelet counts enabling HCV antiviral therapy initiation; not HIV-specific
NCT01636778	Phase 2	Completed	45	SB-497115-GR (eltrombopag) raising platelet counts in HCV-related thrombocytopenia with compensated cirrhosis; not HIV-specific
NCT00529568	Phase 3	Completed	759	Eltrombopag vs placebo maintaining platelet counts to enable HCV antiviral therapy (Peg-IFN α-2b + ribavirin); SVR as endpoint; not HIV-specific
NCT00516321	Phase 3	Completed	687	Eltrombopag vs placebo maintaining platelet counts to enable HCV antiviral therapy (Peg-IFN α-2a + ribavirin); SVR as endpoint; not HIV-specific

Note: All five trials were graded "C" relevance by evidentiary review — none directly enrolled or targeted HIV-infected populations or antiviral endpoints; they primarily address ITP/HCV-related thrombocytopenia, which is eltrombopag's established use.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19932434	2009	Review	Hematology/Oncology Clinics of North America	Chronic infections (HCV, HIV, H. pylori) as causes of secondary/chronic ITP; treating the underlying infection often improves thrombocytopenia
19245929	2009	Review	Seminars in Hematology	Therapeutic strategies for infection-related immune thrombocytopenia, including HCV and HIV
24816314	2014	Review	Internal Medicine Journal	TPO-receptor agonists in ITP of less than 6 months' duration
22185370	2012	Cohort	Platelets	Danish real-world experience with TPO-receptor agonists in refractory ITP, including secondary ITP cases
25504472	2015	Case series	J Int Assoc Provid AIDS Care	TPO-receptor agonists (eltrombopag, romiplostim) as salvage therapy in refractory HIV-associated ITP after HAART optimization
28043314	2016	Case report	J Coll Physicians Surg Pak	Hepatitis B leading to megaloblastic anemia and severe thrombocytopenia (not HIV; adjacent infectious-thrombocytopenia context)
22992580	2012	Case report	AIDS	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia
25333665	2014	Case report	AIDS	Eltrombopag successfully treated aplastic anaemia associated with HIV infection; noted possible immunomodulatory role (↓Th1/Th17, ↑Treg/Th ratio)
24128106	2013	Case report	Farmacia Hospitalaria	Two case reports of eltrombopag for thrombocytopenia in chronic hepatitis C
32977702	2020	In vitro screening	Viruses	Screen of FDA-approved drug library identifies potential modulators of HIV-1 proviral transcription; preliminary, mechanism unconfirmed

Norway Market Information

Eltrombopag is currently not marketed in Norway, and no product authorizations were found in the available data.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence overwhelmingly supports eltrombopag's established use in managing thrombocytopenia that arises as a complication of HIV infection, rather than treating HIV infection directly. The single mechanistic lead for a direct antiviral effect (in vitro HIV-1 transcription screen) is unvalidated. The predicted indication label likely overstates the actual evidentiary link, and the drug is not currently marketed in Norway.

To proceed, the following is needed:

TFDA/Norwegian package insert data (warnings, contraindications) — currently blocking (DG001)
Confirmed mechanism of action data from DrugBank (DG002)
Clarification/re-labeling of the predicted indication to "HIV-associated thrombocytopenia" to align with existing evidence, or dedicated preclinical/clinical validation of the direct antiviral (proviral transcription) mechanism before considering this a genuine HIV-treatment repurposing candidate
Assessment of Norway market entry pathway, given current unmarketed status and zero existing authorizations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.